29 November 2019
Visiongain has launched a new pharma report ‘’Mammalian Polyclonal IgG Antibody Market’’ by Type (Goat, Horse, Mouse, Mouse, Others), Product (Cardiac Biomarkers, Metabolic Biomarkers, Renal Biomarkers, Others), Application (ELISA, Immunoturbidimetry, Immunoelectrophoresis, Immunohistochemistry, Immunocytochemistry, Antibody Identification, Western Blotting), End Users (Academic and Research Centers, Diagnostic Centers, Hospitals), and Geography.
The global mammalian polyclonal IgG antibody market is anticipated to grow at a lucrative CAGR of 5.4% and anticipated to reach USD 1,576.42 Million by 2030.
Advantages over other types of antibodies, growing research and development expenditure, and increased adoption of new diagnostic procedures are few factors that are fueling market growth. For standard laboratory tests such as microarray assays, ELISA, flow cytometry & immunohistochemistry, polyclonal antibodies are often the preferred choice. Also, development of these antibodies does not require professional expertise and large quantities can be manufactured as per end user requirements.
Also, the growth of mammalian polyclonal IgG antibody and advancement in production of antibodies is attributed to growing investment by pharmaceutical and biotech companies. Over the past few years, biotech companies have invested in the development of new and active antibodies and for QC purposes. For example, R&D investments by top 10 biotech companies, rose from USD 8.2 billion in 2010 to USD 10.2 billion in 2016, reflecting a rise of 13 percent.
In the treatment of chronic diseases such as cancer, diabetes, autoimmune diseases and metabolic diseases, mammalian polyclonal IgG antibodies are increasingly being used. The growing use of biomarkers to diagnose reliably and rapidly further boosts the global market. Clinicians are increasingly using CD20 biomarkers for treatment of B-cell lymphoma and leukemia, leading to increased demand for these drugs.
It is anticipated that increased use of metabolic biomarkers for diabetes diagnosis would improve its growth. The International Diabetes Federation's estimates show that in 2017, over 400 million people worldwide suffered from diabetes. Type II diabetes is the most common type of diabetes and it is this form which affects 90 percent of the affected population. Increasing cases of cancer worldwide are also expected to drive the development of the segment in the near future. In the research, other biomarkers are cancer and autoimmune biomarkers.
The rapid developments in diagnostic procedures are also fueling the growth of the global mammalian polyclonal IgG antibody market in developing and developed countries. Increasingly, antibodies are being used to treat B-cell lymphoma and leukemia and give a strong boost to the market. The adoption is further driven by the growing use of biomarkers with greater accuracy and performance in research and healthcare industries. The increasing popularity of autoimmune biomarker cancer treatment has a propellant
North America holds the majority of market share in term of revenue owing to growing investment in polyclone-based IgG antibody production, involvement of leading companies and research organizations in the development of antibodies. It is also anticipated that the rapid adoption of advanced technology and clinical research will further drive market growth in this area.
Asia Pacific (APAC) is anticipated to growth with the highest CAGR over the forecast period from 2020 to 2030 owing to rising disposable income and increased prevalence of cancer and diabetes. Furthermore, leading manufacturers are increasing their focus on strengthening their presence in the emerging economies such as Japan, China, and India.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products in order to strengthen their position in the global mammalian polyclonal IgG antibody market. Companies are also expanding their R&D, distribution, and management facilities in order to expand their business and to hold a competitive edge in the Mammalian Polyclonal IgG Antibody market.
The comprehensive market report features companies such as Abcam plc., Bio-Rad Laboratories, Thermo Fisher Scientific, Merck KGaA, Cell Signaling Technologies, Hoffmann-La Roche Ltd., Genway Biotech, Inc., BioNTech, LigaTrap, CLOUD-CLONE CORP.(CCC), Creative Diagnostics, Abbiotec, Inc., Enzo Life Sciences, Inc., ViroGen, Proteintech Group, Sino Biological Inc. among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020-2030 for global markets such as North America, Latin America, Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Russia, India, Japan, China, Australia, ASEAN, GCC and South Africa.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Some of the major factors fuelling the growth of global market include significant advantages associated with PIM solutions and inclination towards centralized models among across pharma sector.
19 October 2020
The coronavirus outbreak has negatively impacted all the economies and industries across the globe. Hence, for the next 1-2 years, the global respiratory drug delivery market is expected to take a hit.
12 October 2020
We predict strong revenue growth through to 2030. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
02 October 2020
The development of mRNA vaccines is driven by new biotechnologies and nanotechnologies. Emerging delivery technologies, such as electroporation (EP), innovative vaccine formats like mRNA preventive boost, and new molecular adjuvant technologies are particularly important for mRNA vaccines reaching their potential.